Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats

ABSTRACT: Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like R agonists and the progress of myocard...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohammed Fouad Shalaby, MD, Hekma A. Abd El Latif, PhD, Mohamed El Yamani, PhD, May Ahmed Galal, PhD, Sherifa Kamal, PhD, Ikhlas Sindi, PhD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cardiovascular Diabetic nephropathy Dopamine receptors Myocardial injury Sarpogrelate Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4071e837d64440c69aa406399cbef68a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4071e837d64440c69aa406399cbef68a
record_format	dspace
spelling	oai:doaj.org-article:4071e837d64440c69aa406399cbef68a2021-11-04T04:25:42ZProtective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats0011-393X10.1016/j.curtheres.2021.100647https://doaj.org/article/4071e837d64440c69aa406399cbef68a2021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0011393X21000254https://doaj.org/toc/0011-393XABSTRACT: Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like R agonists and the progress of myocardial injury, especially in the early phase of therapy. Objective: This investigation aimed to examine the potential activity of sarpogrelate (a 5-hydroxytryptamine 2A [5-HT2A] receptor blocker) in reducing myocardial injury prompted by extended haul utilization of D2 receptor agonists in a model of diabetic rats. Methods: In the in vivo studies, both bromocriptine and cabergoline were managed independently and combined with sarpogrelate for about a month in diabetic nephropathy rats. Blood glucose level and other myocardial biochemical parameters were estimated. The probable mechanism for insulin secretagogue action was evaluated through in vitro isolated islets study. Sodium/potassium-adenosine triphosphatase activity was assayed in an isolated microsomal fraction of the renal cortex. Isolated perfused rat hearts were treated with different doses of dopamine before and after being subjected to the tested drugs, dose response of heart rate, and heart contractility were recorded. Results: Bromocriptine and cabergoline created a significant reduction in blood glucose level without any action on insulin secretagogues. Bromocriptine prevented the loss of sodium/potassium-adenosine triphosphatase activity in the cortex of an ischemic kidney. Treatment of bromocriptine or cabergoline with sarpogrelate altogether decreased the levels of the elevated myocardial biomarkers in serum. Administration of different doses of dopamine in presence of bromocriptine or capergoline resulted in significantly rising in the heart rate percentage comparing to dopamine alone. A mix of bromocriptine or cabergoline with sarpogrelate diminished both heart rate and contractility, respectively. Conclusions: The examination demonstrated that the combined use of sarpogrelate with bromocriptine or cabergoline decreased the potential adverse effects of these 2 drugs on myocardial tissues.Mohammed Fouad Shalaby, MDHekma A. Abd El Latif, PhDMohamed El Yamani, PhDMay Ahmed Galal, PhDSherifa Kamal, PhDIkhlas Sindi, PhDElsevierarticleCardiovascularDiabetic nephropathyDopamine receptorsMyocardial injurySarpogrelateTherapeutics. PharmacologyRM1-950ENCurrent Therapeutic Research, Vol 95, Iss , Pp 100647- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cardiovascular Diabetic nephropathy Dopamine receptors Myocardial injury Sarpogrelate Therapeutics. Pharmacology RM1-950
spellingShingle	Cardiovascular Diabetic nephropathy Dopamine receptors Myocardial injury Sarpogrelate Therapeutics. Pharmacology RM1-950 Mohammed Fouad Shalaby, MD Hekma A. Abd El Latif, PhD Mohamed El Yamani, PhD May Ahmed Galal, PhD Sherifa Kamal, PhD Ikhlas Sindi, PhD Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats
description	ABSTRACT: Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like R agonists and the progress of myocardial injury, especially in the early phase of therapy. Objective: This investigation aimed to examine the potential activity of sarpogrelate (a 5-hydroxytryptamine 2A [5-HT2A] receptor blocker) in reducing myocardial injury prompted by extended haul utilization of D2 receptor agonists in a model of diabetic rats. Methods: In the in vivo studies, both bromocriptine and cabergoline were managed independently and combined with sarpogrelate for about a month in diabetic nephropathy rats. Blood glucose level and other myocardial biochemical parameters were estimated. The probable mechanism for insulin secretagogue action was evaluated through in vitro isolated islets study. Sodium/potassium-adenosine triphosphatase activity was assayed in an isolated microsomal fraction of the renal cortex. Isolated perfused rat hearts were treated with different doses of dopamine before and after being subjected to the tested drugs, dose response of heart rate, and heart contractility were recorded. Results: Bromocriptine and cabergoline created a significant reduction in blood glucose level without any action on insulin secretagogues. Bromocriptine prevented the loss of sodium/potassium-adenosine triphosphatase activity in the cortex of an ischemic kidney. Treatment of bromocriptine or cabergoline with sarpogrelate altogether decreased the levels of the elevated myocardial biomarkers in serum. Administration of different doses of dopamine in presence of bromocriptine or capergoline resulted in significantly rising in the heart rate percentage comparing to dopamine alone. A mix of bromocriptine or cabergoline with sarpogrelate diminished both heart rate and contractility, respectively. Conclusions: The examination demonstrated that the combined use of sarpogrelate with bromocriptine or cabergoline decreased the potential adverse effects of these 2 drugs on myocardial tissues.
format	article
author	Mohammed Fouad Shalaby, MD Hekma A. Abd El Latif, PhD Mohamed El Yamani, PhD May Ahmed Galal, PhD Sherifa Kamal, PhD Ikhlas Sindi, PhD
author_facet	Mohammed Fouad Shalaby, MD Hekma A. Abd El Latif, PhD Mohamed El Yamani, PhD May Ahmed Galal, PhD Sherifa Kamal, PhD Ikhlas Sindi, PhD
author_sort	Mohammed Fouad Shalaby, MD
title	Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats
title_short	Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats
title_full	Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats
title_fullStr	Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats
title_full_unstemmed	Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats
title_sort	protective role of sarpogrelate in combination with bromocriptine and cabergoline for treatment of diabetes in alloxan-induced diabetic rats
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/4071e837d64440c69aa406399cbef68a
work_keys_str_mv	AT mohammedfouadshalabymd protectiveroleofsarpogrelateincombinationwithbromocriptineandcabergolinefortreatmentofdiabetesinalloxaninduceddiabeticrats AT hekmaaabdellatifphd protectiveroleofsarpogrelateincombinationwithbromocriptineandcabergolinefortreatmentofdiabetesinalloxaninduceddiabeticrats AT mohamedelyamaniphd protectiveroleofsarpogrelateincombinationwithbromocriptineandcabergolinefortreatmentofdiabetesinalloxaninduceddiabeticrats AT mayahmedgalalphd protectiveroleofsarpogrelateincombinationwithbromocriptineandcabergolinefortreatmentofdiabetesinalloxaninduceddiabeticrats AT sherifakamalphd protectiveroleofsarpogrelateincombinationwithbromocriptineandcabergolinefortreatmentofdiabetesinalloxaninduceddiabeticrats AT ikhlassindiphd protectiveroleofsarpogrelateincombinationwithbromocriptineandcabergolinefortreatmentofdiabetesinalloxaninduceddiabeticrats
_version_	1718445324635209728

Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats

Ejemplares similares